📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 3 — QTPP & CQA (OBX-319)

Document ID: M3-QTPP
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q

Quality Target Product Profile & Critical Quality Attributes — OBX-319

The QTPP for OBX-319 (sterile aqueous solution for subcutaneous injection presented in a single-use prefilled syringe and autoinjector) and the CQA risk assessment linking product attributes to safety and efficacy:

OBX-319 is a humanized IgG1 bispecific monoclonal antibody that engages CD19 and CD20 simultaneously on B lineage cells to drive near-complete peripheral B-cell depletion in moderate-to-severe active Systemic Lupus Erythematosus. The molecule is produced in a Chinese Hamster Ovary (CHO) suspension cell culture and purified by a Protein A capture step followed by orthogonal polishing chromatography, low-pH viral inactivation, and nanofiltration. Heterodimeric assembly is directed by an engineered Fc interface (knob-into-hole) with heavy/light chain pairing controlled to minimise mispaired species. Because the two paratopes are arm-specific and the therapeutic effect depends on coordinate CD19/CD20 engagement, the QTPP and the linked control strategy are built around preserving both binding functions, the correct one-plus-one bispecific architecture, and the molecular integrity that governs immunogenicity and pharmacokinetics of a subcutaneously delivered antibody exhibiting target-mediated drug disposition (TMDD). The QTPP is defined prospectively per ICH Q8(R2) and translated into specifications per ICH Q6B; the substance and product development, characterisation, comparability, viral safety, and stability program follow ICH Q11, Q5A(R2), Q5C-Q5E, and Q1A(R2). The product is intended for licensure as a Biologics License Application under 21 CFR Part 601.

Table 1 — Quality Target Product Profile (QTPP)

QTPP element	Target	Basis / rationale
Indication & mechanism	Treatment of moderate-to-severe active SLE via simultaneous CD19 × CD20 engagement and B-cell depletion	Ties every downstream attribute to the depleting mechanism
Molecule	Humanized IgG1 bispecific mAb, CHO-expressed, heterodimeric (knob-into-hole Fc)	Defines identity and correct-assembly expectations
Dosage form	Sterile, preservative-free aqueous solution for injection	Parenteral biologic; no compendial preservative required for single-use presentation
Route & presentation	Subcutaneous; single-use prefilled syringe and disposable autoinjector	Enables the two active dose levels evaluated clinically; injection-volume compatible
Concentration / deliverable dose	Formulated to deliver the labelled subcutaneous dose in an injection volume compatible with prefilled-syringe and autoinjector administration	Supports patient self-administration; drives high-concentration stability requirements
Appearance	Clear to slightly opalescent, colourless to pale-yellow solution, essentially free of visible particulates	Standard release attribute for an injectable mAb
pH, osmolality, excipients	Physiologically compatible buffer, stabiliser, and non-ionic surfactant; near-isotonic; pH controlled within a defined range	Protects conformational stability and mitigates interfacial aggregation of a high-concentration antibody
Identity	Confirmed dual specificity and correct primary structure	Distinguishes the bispecific from monospecific/mispaired species
Potency	Dual, arm-specific target binding and B-cell-depleting activity within defined relative-potency limits	Directly linked to efficacy
Purity / impurities	Predominantly monomeric bispecific heterodimer; product- and process-related impurities controlled to defined limits	Controls efficacy, safety, and immunogenicity
Sterility, endotoxin, particulates	Meets compendial parenteral requirements (sterility, bacterial endotoxin, sub-visible and visible particulates)	Patient safety for an injectable
Viral safety	Assured by cell-substrate characterisation and validated clearance per ICH Q5A(R2)	CHO-derived biologic
Immunogenicity risk	Minimised through aggregate and impurity control	Anti-drug antibody (ADA) formation is expected and clinically monitored
Container-closure	Maintains sterility, container-closure integrity, and low extractables/leachables across shelf life	Protects product quality and dose delivery
Stability / storage	Supports 2-8 °C storage with defined in-use handling; shelf life justified per ICH Q5C/Q1A(R2)	Distribution and patient-use requirements

CQA identification and risk ranking. Each candidate attribute was assessed for its potential impact on safety (including immunogenicity), efficacy, pharmacokinetics, and product consistency, and for the uncertainty in that impact, following ICH Q9 risk-management principles. Attributes with a plausible high-severity impact are designated critical and assigned tighter control regardless of current process capability. The following CQAs were identified, in order of the product's mechanistic and safety hierarchy:

• Dual, arm-specific target binding & potency
• Correct bispecific chain pairing / assembly
• Aggregation (HMW) & fragmentation
• N-glycosylation profile / effector attenuation
• Charge variants (deamidation/isomerisation)
• Host-cell impurities, viral & endotoxin safety

Table 2 — CQA risk assessment and control linkage

CQA	Criticality	Principal impact	Principal analytical control
Dual, arm-specific binding & potency	High	Efficacy (coordinate CD19/CD20 engagement and depletion)	Cell-based depletion/functional bioassay; independent anti-CD19 and anti-CD20 binding assays; simultaneous dual-binding assay (SPR/bridging ELISA)
Correct bispecific chain pairing / assembly	High	Efficacy and immunogenicity	Intact and subunit LC-MS; non-reduced/reduced CE-SDS; HIC; imaged cIEF; limits on homodimers, half-antibodies, and mispaired species
Aggregation (HMW) & fragmentation	High	Immunogenicity/safety and potency	SEC (HMW), CE-SDS (LMW/fragments), sub-visible particles by micro-flow imaging and light obscuration
N-glycosylation profile / effector attenuation	High / Medium	Effector engagement, clearance/PK	Released-glycan map; high-mannose, afucosylation, galactosylation, sialylation monitoring
Charge variants (deamidation/isomerisation)	Medium	Potency (if CDR-localised) and PK	Imaged cIEF / ion-exchange chromatography; peptide mapping with modification site mapping
Host-cell impurities, viral & endotoxin safety	High (safety)	Patient safety and immunogenicity	HCP ELISA; residual CHO DNA (qPCR); residual Protein A; viral clearance per ICH Q5A(R2); bacterial endotoxin (LAL); sterility; bioburden

Dual, arm-specific target binding & potency

Efficacy of OBX-319 depends on both paratopes remaining functional and on the antibody engaging CD19 and CD20 simultaneously. The potency control set therefore combines a mechanism-reflective cell-based assay that measures B-cell binding/depleting activity with orthogonal binding assays that interrogate the anti-CD19 and anti-CD20 arms independently, and a simultaneous dual-binding assay (surface plasmon resonance or bridging format) that confirms one molecule can bridge both antigens. Relative potency is reported against the reference standard within pre-defined acceptance limits. Loss of activity in either arm, or loss of simultaneous engagement, would attenuate the depletion that underlies the observed clinical B-cell reduction and biomarker normalisation, so this CQA is designated critical and is anchored in both drug-substance and drug-product release and stability testing.

Correct bispecific chain pairing / assembly

The defining product-related risk for a two-chain bispecific is incorrect assembly. Engineered Fc heterodimerisation and controlled heavy/light chain pairing are used to favour the desired one-plus-one architecture; nonetheless, homodimers, half-antibodies, and light-chain-mispaired species can arise and are treated as product-related impurities. Correct assembly is confirmed and quantified by intact-mass and subunit LC-MS, non-reduced and reduced CE-SDS, hydrophobic-interaction chromatography, and imaged cIEF, with acceptance limits on the total mispaired/assembly-variant burden. Mispaired species can be functionally monovalent or non-functional and may carry altered immunogenicity risk, so their control is directly coupled to the potency and safety objectives of the QTPP.

Aggregation (HMW) & fragmentation

As a high-concentration antibody delivered subcutaneously, OBX-319 is sensitive to aggregation driven by concentration, interfacial stress, and thermal/mechanical stress during manufacture, shipping, and device actuation. High-molecular-weight species are the aggregation-related attribute of greatest concern because sub-visible and soluble aggregates are a recognised driver of immunogenicity, which is clinically relevant given the expected formation of anti-drug antibodies. Fragmentation generates low-molecular-weight species that can reduce potency. Control uses size-exclusion chromatography for HMW, CE-SDS for fragments, and sub-visible particle counting by micro-flow imaging and light obscuration against compendial parenteral limits, supported by the formulation (buffer, stabiliser, and non-ionic surfactant) and by container-closure and device compatibility studies.

N-glycosylation profile / effector attenuation

The Fc N-glycan governs Fcγ-receptor and complement engagement and therefore the effector contribution to B-cell depletion, as well as clearance behaviour relevant to the molecule's TMDD-driven pharmacokinetics. The released-glycan profile is characterised and monitored for afucosylation (which modulates antibody-dependent cellular cytotoxicity), galactosylation (which modulates complement-dependent cytotoxicity), sialylation, and high-mannose content (which can accelerate clearance). The target profile is defined to deliver the intended, attenuated effector engagement consistent with the depletion mechanism while limiting excessive effector-driven cytokine release that could aggravate injection/infusion reactions. Glycosylation is controlled through the cell line, media, and process parameters and verified by the glycan map at drug substance.

Charge variants (deamidation/isomerisation)

Charge heterogeneity arises from asparagine deamidation, aspartate isomerisation, N-terminal pyroglutamate formation, and C-terminal lysine processing. These modifications are quality-relevant primarily when they occur within a complementarity-determining region, where they can reduce binding and hence potency of the affected arm, and secondarily because charge distribution can influence subcutaneous absorption and clearance. Charge variants are monitored by imaged cIEF and/or ion-exchange chromatography at release and on stability, with peptide mapping used to localise and quantify the principal modification sites and to confirm that acidic and basic variant levels remain within limits shown not to affect potency or safety.

Host-cell impurities, viral & endotoxin safety

Process-related impurities from the CHO platform and the Protein A/polishing purification train are controlled to protect patient safety and to limit immunogenicity. Host-cell protein is measured by a qualified ELISA, residual CHO DNA by qPCR (controlled to the low nanogram-per-dose range with demonstrated fragment-size reduction), and residual Protein A leachate by a specific immunoassay; additional process residuals are cleared and, where warranted, monitored. Viral safety is assured per ICH Q5A(R2) through cell-substrate and cell-bank characterisation (ICH Q5D), avoidance and monitoring of adventitious agents, and a validated clearance package spanning low-pH inactivation, chromatographic partitioning, and virus-retentive nanofiltration, with defined log-reduction claims. Bacterial endotoxin is controlled by LAL against a limit derived from the 5 EU/kg/hour threshold for the subcutaneous route, and sterility, bioburden, and container-closure integrity complete the parenteral safety controls. Because the severity of an uncontrolled adventitious-agent or endotoxin event is high, these attributes are treated as critical irrespective of routine process capability.

Each CQA is risk-ranked and mapped to the control strategy (3.2.S.4/3.2.P.5). ICH Q8(R2)/Q9/Q11. The control strategy allocates each attribute across the cell line and cell-bank system, in-process controls and process parameters, and drug-substance/drug-product specifications, with comparability governed by ICH Q5E and stability-indicating methods supporting the shelf-life claim under ICH Q5C/Q1A(R2). This linkage ensures that the attributes most consequential for the safety, immunogenicity, pharmacokinetics, and efficacy of a CHO-derived bispecific B-cell-depleting antibody are assured lot-to-lot across the product lifecycle.